Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Incontinentia pigmenti
Incontinentia pigmenti
Incontinentia pigmenti
Synonyms: Bloch-Siemens syndrome, Bloch-Sulzberger syndrome
Synonyms: Bloch-Siemens syndrome, Bloch-Sulzberger syndrome
Synonyms: Bloch-Siemens syndrome, Bloch-Sulzberger syndrome
Drug discovery
113
papers
On emerging therapies
Rare developmental defect during embryogenesis
Incontinentia pigmenti
Overview
Incontinentia pigmenti (IP) is a rare X-linked dominant genodermatosis caused by IKBKG gene mutations, disrupting NF-κB signaling. It primarily affects females, with multisystem involvement: distinctive cutaneous stages (vesicular, verrucous, hyperpigmented, atrophic), retinal vasculopathy, dental anomalies, and CNS risks (seizures, stroke, developmental delay). Diagnosis relies on clinical criteria and genetic testing. Males typically exhibit embryonic lethality or mosaic survival.
Therapies
Symptomatic care: Topical steroids for skin lesions, antiseizure medications (e.g., levetiracetam), and corticosteroids for CNS inflammation [3][13][16].
Ocular interventions: Retinal laser therapy to prevent detachment; lifelong ophthalmologic monitoring [7][8].
Multidisciplinary management: Dermatology, neurology, ophthalmology, and dentistry for dental hypoplasia/alopecia [8][17].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases, rare odontological diseases, rare ophthalmic disorders, rare skin diseases
Research Papers
113 drug discovery papers about Incontinentia pigmenti. Recent publications:
113 drug discovery papers about Incontinentia pigmenti. Recent publications:
categories:
Small molecules
antibodies
2025-12-08 | Whole Exome Sequencing in Incontinentia Pigmenti: A ROP Mimicker and the Genetic Detection Dilemma.
Incontinentia pigmenti is an X-linked dominant multisystemic disorder caused by pathogenic variants in the inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG) gene. Mutations in the IKBKG gene, encoding the NF-kappa-B essential modulator protein, underlie its pathogenesis, leading to inflammation-driven vascular ischemia and significant ocular manifestations. The authors report a case of an Asian-Indian infant diagnosed as having stage 3 incontinentia pigmenti in both eyes treated with anti-vascular endothelial growth factor and laser photocoagulation where standard whole exome sequencing failed to reveal pathogenic variants. This case emphasizes the need for a multi-disciplinary approach to early diagnosis and intervention, and the challenges in genetic testing when dealing with rare diseases in resource-limited settings.
2022-10-11 | Incontinentia pigmenti and the eye.
Incontinentia pigmenti (IP) is a rare X-linked dominant phakomatosis that predominately presents with dermatologic manifestations but can also cause central nervous system and ocular abnormalities. Awareness of the ocular complications of IP is crucial to identify ocular abnormalities early and prevent permanent vision loss. There have been significant recent advances in ocular diagnostic imaging in IP. Optical coherence tomography (OCT) has helped characterize outer plexiform layer abnormalities in the macula, which can help explain central vision loss in IP patients. OCT angiography (OCT-A) also identifies macular vascular changes that induce these foveal structural abnormalities and may supplement fluorescein angiography, the current standard of care to identify peripheral retinal ischemia and neovascularization for infants with IP. Additionally, recent studies have presented excellent anatomic outcomes years after laser photocoagulation to ischemic retina. Early data indicates that antivascular endothelial growth factor therapy can induce retinal revascularization, but runs the risk of late recurrent neovascularization and requires long-term monitoring. Ophthalmic imaging is evolving in the evaluation of IP and is increasingly guiding treatment modalities. A particular focus on the ocular manifestations of IP has been the ideal treatment for retinopathy in this disorder.
2021-12-21 | Case Report: A Case of Cotton-Wool Spots After Intravitreal Injection of Conbercept in an Infant With Incontinentia Pigmenti
Introduction: Incontinentia pigmenti (IP) is a rare X-linked neuroectodermal dysplasia affecting multiple organs. One of its most significant ophthalmic manifestations is retinal neovascularization due to retinal ischemia, which has been traditionally treated with laser photocoagulation or cryotherapy. The application of anti-vascular endothelial growth factor (VEGF) has been reported for the treatment of retinopathy of IP with beneficial results. However, clinicians should be aware of the possible ocular and systemic side effects of the intravitreal injection of anti-VEGF agents. Case Report: A 4-month-old female infant with IP was treated with intravitreal injection of conbercept in both eyes. However, cotton-wool spots were noticed in the left eye 1 week after the injection. Laser photocoagulation was performed as an adjunct treatment. The cotton-wool spots were absorbed 1 month after the first intravitreal injection and have eventually disappeared. Discussion: The cotton-wool spots, after intravitreal injection of conbercept for the treatment of IP, indicated severe retinal ischemia resulting from the neutralization of excessive VEGF, which was shown on fundus photograph and fluorescent angiography. Anti-VEGF agents could cause retinal arteriolar vasoconstriction and artery occlusion on rare occasions. The administration of anti-VEGF agents in pediatric cases with severe neovascularization and retinal ischemia should be carefully considered.
2020-10-22 | Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report.
Incontinentia Pigmenti is a rare disease affecting multiple organs. Fifty of patients show affection of the eye with retinopathy and possible amaurosis being the worst outcome. Treatment has commonly been panretinal laser coagulation but intravitreal application of bevacizumab as VEGF-inhibitor has shown to effectively suppress retinal neovascularization. A six-week-old female infant with Incontinentia Pigmenti developed a foudroyant necrotizing enterocolitis shortly after intravitreal injection of bevazicumab due to a retinopathy with impending tractional detachment of the left eye. Since the onset of abdominal symptoms occurred immediately after the intravitreal application, a link between the two events seemed likely. Sequential analyses of the VEGF serum concentrations showed a massive suppression of endogenous VEGF with only a very slow recovery over weeks. Such a severe systemic adverse event has not been reported after intravitreal treatment with bevacizumab in an infant. This case report shows a relevant systemic uptake of bevacizumab after intravitreal application as suppressed VEGF levels show. There seems to be a connection between suppressed VEGF levels and the onset of necrotizing enterocolitis. Therefore, treatment with bevacizumab should be carefully considered and further research is needed to assess this drug's safety profile.
2019-04-18 | [Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor].
Objective: To investigate the treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor. Methods: Retrospective study of 5 patients(8 eyes) diagnosed retinopathy of incontinentia pigmenti from 2005 to 2017, including 0 males and 5 females (8 eyes involved) with an average age of 2.4 months(range, 1-5 months). Medical history and family history were recorded in detail for all children. We did the examination of anterior segment of the eyeball, vitreous body,fundus and intraocular pressure for the 5 patients(8eyes).What's more,wo also took pictures for fundus with the machine of Retcam. Fundus fluorescence angiography (FFA) was performed in 2 patients(4 eyes). Different surgical methods were selected according to the specific conditions of the eye and postoperative were observed. Results: At the time of initial diagnosis, preretinal hemorrhage did not affect the macular region in 3 cases (5 eyes), pre retinal hemorrhage affected the macular region in 1 case(1 eye), the retinal neovascularization in 3 cases(5 eyes), the retinal detachment in 2 cases(2 eyes), and nonvascular zone of peripheral retinal in 5cases(8 eyes). Treatment and drug selection: 3 cases(5 eyes) were treated with injection anti-VEGF drug into vitreous body cavity, 1 case(1 eye) was treated with injection anti-VEGF drug into vitreous body cavity plus laser photocoagulation, 1 case(1 eye) was treated with anti-VEGF drugs plus vitrectomy. 1 case(1 eye) was treated with anti-VEGF drugs plus retinal cryotherapy and sclera bucking. In patients of injection anti-VEGF drug into vitreous body cavity, 2 cases(3 eyes) were given a single dose and 1 case (2 eyes) was given a repeated dose. Drug selection: 4 cases(6 eyes) ranibizumab injection (injection dose 0.025 ml), 1 case (2 eyes)conbercept injection (injection dose 0.025 ml). To follow-up date, etina was flat in 4 patients (7 eyes), epiretinal membrane in 2 patients(2 eyes), retinal detachment in 1 patient(1 eye). Conclusions: The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. (Chin J Ophthalmol, 2019, 55:294-301). 目的: 探讨色素失禁症相关性视网膜病变的临床表现及抗血管内皮生长因子治疗效果。 方法: 回顾性系列病例研究。收集2005至2017年确诊的5例色素失禁症相关性视网膜病变患儿的临床资料。患儿均为女性,就诊年龄1~5个月,平均2.4个月。详细记录患儿病史及家族史,5例(10只眼)均行眼前节检查、玻璃体检查、眼底检查和眼压检查,并用Retcam系统行眼底照相,其中2例(4只眼)曾行荧光素眼底血管造影检查。根据患儿眼底具体情况选择单纯玻璃体腔注药术、玻璃体腔注药术联合激光光凝治疗或玻璃体腔注药术联合玻璃体切除术等,观察术后效果。 结果: 初诊时视网膜前出血未累及黄斑区3例(5只眼),黄斑区视网膜前出血1例(1只眼),视网膜新生血管3例(5只眼),视网膜脱离2例(2只眼),周边无血管区5例(8只眼)。视网膜前出血未累及黄斑区5只眼中有3只眼累及视网膜4个象限,2只眼累及颞上、颞上2个象限。治疗方案及药物选择:3例(5只眼)单纯玻璃体腔注射抗VEGF药物治疗,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加激光光凝,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加玻璃体切除术,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加视网膜冷冻术及外加压术。在单纯玻璃体腔注射抗VEGF药物治疗患者中有2例(3只眼)单次给药,1例(2只眼)多次重复给药。注射药品选择4例(6只眼)雷珠单克隆抗体(注射剂量0.025 ml),1例(2只眼)康柏西普(注射剂量0.025 ml)。至随访日,4例(7只眼)患儿视网膜在位,2例(2只眼)可见视网膜前增生膜,1例(1只眼)视网膜脱离。 结论: 初步证实了抗血管内皮生长因子药物在色素失禁症相关性视网膜病变治疗中的有效性。但最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。(中华眼科杂志,2019,55:294-301).
small molecules
2026-04-01 | AN AYURVEDIC APPROACH IN THE MANAGEMENT OF HYPOMELANOSIS OF ITO: A CASE REPROT
Background: Hypomelanosis of Ito (HOI) is a neurocutaneous disorder characterized by bizarre, bilateral and irregularly shaped leukoderma affecting the trunk and extremities, often associated with neurological and musculoskeletal abnormalities. It is also called incontinentia pigmenti achromians and is the third most common neurocutaneous disorder after Neurofibromatosis and Tuberous sclerosis. Considering the symptomatology, this condition can be correlated as Sahaja Sarvangavatam (diseases due to vata affecting the whole body) with Vyanavrutha Vatha (subtype of vata) and skin involvement is predominantly visible. Objective: The article highlights the scope of an integrated approach in treating neurocutaneous disorders, combining Ayurvedic intervention along with physiotherapy. Methodology: This is a case study of a 4-year-old child presenting with hypomelanotic areas on extensor part of right arm by birth, seizure disorder, mild hearing loss, inability to sit without support and mild spasticity of bilateral lower limbs. He visited the outpatient department of our tertiary Ayurvedic Health Centre and took outpatient management for about two weeks with the administration of Ashwagandharishtam, Rajanyadi churnam, Kalyanavaleha churnam, Priyalamajjadi modakam and Mahanarayana tailam. IP management was also taken along with dietary recommendations for about one month and twelve days with the line of management of Vatavyadhi (diseases caused by Vata) Chikitsa (treatment) along with Samana oushadhas (palliative medicines). The outcome was assessed using Ages and Stages Questionnaire before and after the treatment. Result: Head holding was improved from Grade 4 to Grade 5 with reduction in the spasticity of bilateral lower limbs. Crawling was attained with reduction in drooling and colour of the hypopigmented patches got mildly regressed along with initiation of new sounds and words with no further episodes of seizures. The Ages and Stages Questionnaire improved from 195 to 245, providing valuable insights into management strategies. Conclusion: An integrated approach involving Ayurveda and physiotherapy provides a sustainable solution in improving the quality of life of the child.
2026-04-01 | Clearance of Verrucous Stage of Incontinentia Pigmenti with Condy’s Solution
A 10-month-old female child born out of a consanguineous marriage presented with thick, dirty, warty hyperpigmented lesions with episodes of serosanguineous discharge on the left lower limb since 2 months of age. Her left side abdomen and arm also had mild lesions in a blaschkoid pattern. A diagnosis of verrucous stage Incontinentia Pigmenti was made with the help of histopathology evaluation. Initially, she was given oral and topical antibiotics for management, but the lesions did not heal completely. Then, the parents were advised to prepare Condy’s solution and use it for soaking the lesions for 5–10 min on oozing lesions. After performing this therapy for 2 months, a drastic response was seen in the lesions as the discharge had stopped and crusting had reduced by 60% [Figures 1 and 2]. Gradually, the frequency of application was reduced to twice a week and then completely halted after 1 month.Figure 1: Visual comparison of Pre (a) and Post (b) therapy images of lateral aspect of child’s left lower limb showing the decrease in hyperpigmented, warty, oozing lesions after Condy’s soaksFigure 2: Visual comparison of Pre (a) and Post (b) therapy images of dorsal aspect of left foot with clear improvementCondy’s solution used for medicinal purposes is made by dissolving 400 mg of potassium permanganate in 4 L of water to attain 1:10,000 dilution.[1] However, in clinical practice, patients are explained to dilute the solution to reach a color similar to the pink color of one’s nail bed. It has astringent properties that help in drying up the weeping lesions along with rendering antibacterial and anti-inflammatory properties. Using Condy’s soaks for Incontinentia pigmenti in this case makes it worthwhile exploring further in clinical practice. Declaration of consent The authors certify that they have obtained all appropriate consent forms, duly signed by the parent(s)/guardian(s) of the patient. In the form, the parent(s)/guardian(s) has/have given his/her/their consent for the images and other clinical information of their child to be reported in the journal. The parents understand that the names and initials of their child/children will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
2025-02-28 | Single-Cell RNA Sequencing in Incontinentia Pigmenti With Neonatal Encephalopathy Reveals Broad Immune Activation Moderated by Steroids.
DNA variations in the NF-kappa-B essential modulator (NEMO) gene are linked to incontinentia pigmenti (IP) and also immunodeficiency and autoinflammatory conditions. Some patients with IP present with neonatal vasculitis-like brain changes, although pathogenesis is unclear. We investigated cell-specific gene expression in a neonate with IP, who had encephalopathy, seizures, and vasculitis-like brain changes, and responded to steroid treatment. Single-cell RNA (ribonucleic acid) sequencing (scRNAseq), using the HIVE single-cell system, was performed on a neonate with IP, before and after steroid treatment, compared with a sex-matched healthy control toddler. A total of 20,411 cells were sequenced and clustered into 10 cell types. In IP compared with control, upregulated significant gene set enrichment analysis gene ontology pathways (FDR <0.05) included defense response, complement activation, humoral immune response, and phagocytosis across all cell types. After steroid treatment, these pathways were predominantly downregulated in monocytes and neutrophils. The upregulated genes in IP that became downregulated after steroid treatment were interferon-related genes, oligoadenylate synthases, and immunoglobulin genes. IP-associated loss of NEMO function is associated with a proinflammatory phenotype, that is moderated by steroids. scRNAseq provides a rationale for immune modulation in an n = 1 setting and valuable insights into the pathogenesis and therapeutics of this rare disease.
2025-01-30 | Case Report: Diagnosis and treatment of incontinentia pigmenti with central nervous system anomalies in one patient.
This article reports a detailed case of a patient with incontinentia pigmenti who exhibited epileptic status and dermatologic symptoms. A 5-month-old female patient was brought to our hospital due to status epilepticus, with erythematous vesicular skin lesions on her trunk and extremities. Routine magnetic resonance imaging revealed infarction, ischemia, and encephalomalacia. Skin biopsy pathology indicated pigmentation disorder. Molecular genetic testing was conducted to identify IKBKG mutations, and the case was finally diagnosed with incontinentia pigmenti complicated by central nervous system anomalies. She was treated with oral levetiracetam (10 mg/kg/day, administered every 12 h) to control her recurrent seizures, and prednisone (1 mg/kg/day, once a day) for anti-inflammatory effects. After nine months, her skin lesions have resolved, with only a few newly developed erythematous papules and areas of hyperpigmentation being evident. There were no recurrent epilepsy symptoms, developmental impairments, or other associated symptoms.
2024-10-24 | Incontinentia pigmenti: a rare cause of skin rash in newborn
Incontinentia pigmenti (IP) is a genodermatosis caused by mutations in the NEMO gene (Xq28) and is lethal in males. It is an X-linked dominant disorder with multi-systemic involvement. It involves the central nervous system and ectodermal tissues like skin, teeth, hair, nails, eyes, and the commonest manifestations are cutaneous manifestations. Here we present a case of a female newborn with vesico bullous eruption presented at birth. A full-term newborn female patient born by LSCS presented at birth with multiple vesico bullous skin lesions over bilateral upper and lower limbs in a pattern consistent with Blaschko's lines. Maternal HIV, HBsAg, VDRL, and TORCH screening were negative. Systemic examinations were normal. Supportive care and IV antibiotics with IV acyclovir were started but without any response. The sepsis screen, blood, and urine culture were negative. ANA was negative. Wound swab culture and skin culture were negative. Skin biopsy results showed eosinophilic infiltration of the dermis and spongiosis. Genetic testing could not be done. Topical steroids were prescribed. The diagnosis of Incontinentia pigmenti was established based on the patient's skin lesions and biopsy results. The baby improved and was discharged on the 14th day of life on topical steroids and is currently under follow-up. Other dermatologic conditions, like mastocytosis and hereditary epidermolysis bullosa, should be considered in the differential diagnosis of Incontinentia pigmenti. The diagnosis of Incontinentia pigmenti should be confirmed by histopathological examination of biopsy specimens along with genetic testing. It is a systemic disorder, so clinical management should include a multidisciplinary approach.
gene therapies
2026-06-22 | Simultaneous trophectoderm biopsies enable preimplantation genetic testing for monogenic disorders in de novo case of incontinentia pigmenti: case report.
To describe the use of two simultaneous trophectoderm biopsies as a method to establish linkage analysis for preimplantation genetic testing for monogenic disorders (PGT-M) test development in a case of de novo incontinentia pigmenti (IP). Case report. A 29-year-old nulligravid woman with de novo IP, confirmed to have the common, large deletion of exons 4-10 in the IKBKG gene. Negative maternal testing confirmed the mutation was de novo in our patient. Two simultaneous trophectoderm biopsies from a minimum of four embryos were obtained to enable two independent deoxyribonucleic acid preparations. This approach was utilized to complete linkage analysis, facilitating successful test development for PGT-M. PGT-M test development and subsequent intracytoplasmic sperm injection/PGT-M cycle targeting the IKBKG deletion. PGT-M test development was successful. The patient underwent two antagonist stimulation protocols with intracytoplasmic sperm injection and PGT-M, yielding 10 euploid embryos that tested negative for the IKBKG deletion and were deemed suitable for transfer. PGT-M for de novo IP is particularly challenging given the presence of the IKBKGP1 pseudogene, its terminal location, and the fact that indirect linkage analysis is necessary for large gene deletions. Without genetic information from parents and offspring, PGT-M test development is frequently unsuccessful. This case demonstrates that simultaneous trophectoderm biopsies can enable PGT-M in otherwise ineligible cases, offering a viable path forward for patients affected by de novo IP.
2026-05-30 | Incontinentia pigmenti: exploring the oral manifestations.
Incontinentia pigmenti (IP) is a rare genetic condition which is X-linked and predominantly affects the structures arising from neuroectodermal origin such as the skin, teeth, eyes, hair, nails and central nervous system. The dermatological manifestations are seen as the first developing signs. The dental manifestations are also commonly seen. Here we discuss a case of a girl in her early adolescence who was diagnosed with a case of IP. The dental features present in this case were typical, including missing permanent teeth, retained deciduous teeth, microdontia and delayed eruption.
2026-05-06 | Asymptomatic Sight-Threatening Retinopathy in Multisystem Incontinentia Pigmenti
A 9-year-old girl had a history of fulminant systemic autoinflammation from birth, manifesting as acute respiratory failure, hand tremors, and generalized cutaneous erythema.Brain magnetic resonance imaging revealed cerebral injury, and laboratory tests showed markedly elevated inflammatory markers, including C-reactive protein and erythrocyte sedimentation rate.At 20 months of age, she was hospitalized for life-threatening Aspergillus pneumonia complicated by liver dysfunction.During this period, a diagnosis of incontinentia pigmenti (IP) was established.
2026-01-27 | A Fulminant Case of Incontinentia Pigmenti Presenting With Early Neuro-Ophthalmologic Manifestations.
Incontinentia pigmenti (IP) is a rare, X-linked dominant, multisystemic genetic disorder. We report the case of a female neonate presenting with vesiculobullous and erythematous cutaneous lesions involving the hands and feet. Concurrently, she exhibited repetitive flexion movements of all four limbs, which rapidly progressed to status epilepticus. The clinical course was rapidly unfavorable, marked by diffuse retinal ischemia and cerebral palsy. This patient's clinical history illustrates the potential severity of the neurological and ophthalmologic manifestations of IP. It underscores the need to consider IP in the differential diagnosis of cutaneous lesions associated with neurological symptoms in female infants. Early recognition is essential to ensure close monitoring and initiate appropriate multidisciplinary management.
2025-12-19 | O05 Incontinentia pigmenti: clinical heterogeneity and the role of early dermatological recognition.
Incontinentia pigmenti (IP) is a rare X-linked dominant genetic condition affecting the skin, teeth, eyes and central nervous system. It is most frequently caused by a common deletion of exons 4-10 in the IKBKG gene. Skin manifestations classically evolve through four stages: blistering, verrucous, hyperpigmentation and hypopigmentation. We conducted a retrospective review of patients attending our tertiary centre since 2000. The study aim was to classify the cutaneous phases of IP and other system involvement in our cohort. 44 patients were included, identified through our electronic health record system. Patient data were anonymised and analysed in SPSS. 93% were female. Mean age of presentation was 20 months, with 68% <6 months. 67% had cutaneous manifestations at birth. Not all patients followed the four classical stages of IP: 91% experienced blistering, 61% verrucous stage, 84% hyperpigmentation and 22.7% hypopigmentation. 18% had hair and 16% nail abnormalities. Mean follow-up duration was 5 years. To confirm IP diagnosis, 23% had a skin biopsy and 96% had genetic testing. 75% had the common IKBKG deletion. Of 3 male patients, all had normal karyotypes and 2 had common deletion of IKBKG, suggestive of mosaic IP. Most patients had extra-cutaneous involvement. 60% had ocular manifestations, with 48% requiring laser treatment. 27% had neurological involvement and 71% dental abnormalities. IP typically presents with cutaneous manifestations, giving dermatologists a crucial role in diagnosis. Our review highlights that patients may not exhibit the textbook presentation of IP. Early recognition has important implications for sight preservation and monitoring of neurodevelopment.
proteins
2026-06-28 | Coexistence of Incontinentia Pigmenti and Pituitary Aplasia in a Female Child
Incontinentia pigmenti (IP) is a rare X-linked dominant neurocutaneous ectodermal disorder. It is caused by IKBKG gene mutations, leading to nuclear factor-kappa B (NF-kB) signaling pathway dysfunction. Skin involvement occurs in almost all patients. IP may also involve teeth, eyes, hair, central nervous system, bone structures, skeletal musculature and immune system. However, endocrine involvement, and specifically the coexistence of IP with complete pituitary aplasia, has not been previously documented in a patient with genetically confirmed IP. We describe a four-year-old female with genetically confirmed IP referred to Paediatric Endocrinology clinic due to short stature and poor growth velocity. Investigation revealed pituitary aplasia with ectopic neurohypophysis. The patient initiated hormone replacement therapy with recombinant human growth hormone and hydrocortisone, followed separately by desmopressin, with significant clinical improvement and no exacerbation of cutaneous manifestations. To our knowledge, this is the first documented case of complete pituitary aplasia in a patient with genetically confirmed IP, with a three-year clinical follow-up.
2024-10-01 | Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.
Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO variants, from 99 kindreds in 10 countries. Forty-seven of these patients (36%) have auto-Abs neutralizing IFN-α and/or IFN-ω, a proportion 23 times higher than that for age-matched female controls. This proportion remains stable from the age of 6 years onward. On imaging, female patients with IP have a small, abnormally structured thymus. Auto-Abs against type I IFNs confer a predisposition to life-threatening viral diseases. By contrast, patients with IP lacking auto-Abs against type I IFNs are at no particular risk of viral disease. These results suggest that IP accelerates thymic involution, thereby underlying the production of auto-Abs neutralizing type I IFNs in at least a third of female patients with IP, predisposing them to life-threatening viral diseases.
2010-06-07 | Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology
NF-kappaB Essential MOdulator (NEMO) has been shown to play a critical role in NF-kappaB activation, as the regulatory subunit of IkappaB kinase. Upon cell stimulation, NEMO can be modified through phosphorylation, sumoylation or ubiquitination. In the latter case, not much is known regarding the exact function of this posttranslational modification. One of the E3 ligase responsible for K63-linked NEMO polyubiquitination is TRAF6, which participates in several signaling pathways controlling immunity, osteoclastogenesis, skin development and brain functions. We previously observed a potentially important interaction between NEMO and TRAF6. In this study, we defined in more detail the domains required for this interaction, uncovering a new binding site for TRAF6 located at the amino-terminus of NEMO and recognized by the coiled-coil domain of TRAF6. This site appears to work in concert with the previously identified NEMO ubiquitin-binding domain which binds polyubiquitinated chains, suggesting a dual mode of TRAF6 recognition. We also showed that E57K mutation of NEMO found in a mild form of the genetic disease incontinentia pigmenti, resulted in impaired TRAF6 binding and IL-1beta signaling. In contrast, activation of NF-kappaB by TNF-alpha was not affected. These data demonstrate that NEMO/TRAF6 interaction has physiological relevance and might represent a new target for therapeutic purposes.
2006-11-29 | Deletion of the N-terminus of IKKγ induces apoptosis in keratinocytes and impairs the AKT/PTEN signaling pathway
The regulatory subunit IKKγ/NEMO is crucial for skin development and function and although devoid of kinase activity, loss of IKKγ function completely abolishes the activation of NF-κB by all pro-inflammatory cytokines. To inhibit the IκB kinase (IKK) complex in keratinocytes, we have used a dominant negative approach by generating stable transfectants of an N-terminal deletion of IKKγ (IKKγ-DN97) that uncouples formation of the IKK complex. Expression of this mutant in PB keratinocytes (PB-IKKγ-DN97) delayed growth kinetics, caused morphological changes and dramatically augmented apoptosis even in the absence of pro-apoptotic stimuli, as determined by cell morphology, TUNEL and caspase-3 cleavage. Moreover, in PB-IKKγ-DN97 cells, TNF-α and IL-1 treatment failed to induce degradation of IκBα, phosphorylation of p65 on Ser 536 and nuclear translocation which, consequently, reduced κB-binding activity. In PB-IKKγ-DN97 cells, accumulation of IκBα correlated with a downregulation of AKT activity and an increase of PTEN protein levels whereas pro-apoptotic p53 target genes Bax and Puma were upregulated. These effects were most likely mediated through IKK since coexpression of the wild-type form of IKKγ in keratinocytes partially reversed apoptosis and reduced PTEN expression. Thus, our data suggest a negative cross-talk mechanism involving PTEN and NF-κB, critical for the anti-apoptotic role of NF-κB in keratinocytes.
other
2025-07-08 | [Application of long-read sequencing based haplotype construction in preimplantation genetic testing for a patient with Incontinentia pigmenti].
To provide preimplantation genetic testing (PGT) for a patient with Incontinentia pigmenti (IP) due to IKBKG gene variant but without family samples through construction of single nucleotide polymorphism (SNP)-based haplotype by Long-read sequencing (LRS) technology. A female IP patient with a heterozygous IKBKG c.1167dup variant but without family genetic data who sought genetic counseling at Women and Children' Hospital of Ningbo University in November 2021 was selected as the study subject. The IKBKG gene has a highly homologous pseudogene IKBKGP1. Genomic DNA was extracted from peripheral blood samples from the couple, and LRS was used to obtain informative SNP loci flanking the variant locus, enabling the construction of SNP haplotype with a long segment spanning from the non-homologous region of IKBKG to the variant site. Trophoblast cells were biopsied from blastocysts fertilized through intracytoplasmic sperm injection, and next-generation sequencing (NGS) was used to determine the SNP information of the embryos. Linkage analysis with the parental SNP haplotypes was conducted to detect the carrier status of the embryos and exclude chromosomal aneuploidies. Sanger sequencing was carried out to validate the result. A euploid embryo without the pathogenic variant was selected for transfer. Prenatal diagnosis was carried out by amniocentesis at mid-trimester to verify the result of PGT tests, and follow-up was conducted after the baby was born. This study has been approved by the Ethics Committee of Women and Children's Hospital of Ningbo University (Ethics No. EC2023-094). A total of seven blastocysts were tested, and PGT results indicated that two embryos were euploid and did not carry the pathogenic variant. One euploid embryo was transferred, which resulted in a singleton pregnancy. Amniocentesis at 24 weeks of gestation confirmed that the status of fetal IKBKG gene, and its chromosomal status was consistent with the PGT results. A healthy male infant was born at 38+6 weeks of gestation. For IP patients with de novo mutation or without family genetic samples, PGT with LRS can directly construct the SNP-based haplotype while avoiding interference from pseudogenes, providing an effective strategy for PGT.
antibodies
2025-12-08 | Whole Exome Sequencing in Incontinentia Pigmenti: A ROP Mimicker and the Genetic Detection Dilemma.
Incontinentia pigmenti is an X-linked dominant multisystemic disorder caused by pathogenic variants in the inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG) gene. Mutations in the IKBKG gene, encoding the NF-kappa-B essential modulator protein, underlie its pathogenesis, leading to inflammation-driven vascular ischemia and significant ocular manifestations. The authors report a case of an Asian-Indian infant diagnosed as having stage 3 incontinentia pigmenti in both eyes treated with anti-vascular endothelial growth factor and laser photocoagulation where standard whole exome sequencing failed to reveal pathogenic variants. This case emphasizes the need for a multi-disciplinary approach to early diagnosis and intervention, and the challenges in genetic testing when dealing with rare diseases in resource-limited settings.
2022-10-11 | Incontinentia pigmenti and the eye.
Incontinentia pigmenti (IP) is a rare X-linked dominant phakomatosis that predominately presents with dermatologic manifestations but can also cause central nervous system and ocular abnormalities. Awareness of the ocular complications of IP is crucial to identify ocular abnormalities early and prevent permanent vision loss. There have been significant recent advances in ocular diagnostic imaging in IP. Optical coherence tomography (OCT) has helped characterize outer plexiform layer abnormalities in the macula, which can help explain central vision loss in IP patients. OCT angiography (OCT-A) also identifies macular vascular changes that induce these foveal structural abnormalities and may supplement fluorescein angiography, the current standard of care to identify peripheral retinal ischemia and neovascularization for infants with IP. Additionally, recent studies have presented excellent anatomic outcomes years after laser photocoagulation to ischemic retina. Early data indicates that antivascular endothelial growth factor therapy can induce retinal revascularization, but runs the risk of late recurrent neovascularization and requires long-term monitoring. Ophthalmic imaging is evolving in the evaluation of IP and is increasingly guiding treatment modalities. A particular focus on the ocular manifestations of IP has been the ideal treatment for retinopathy in this disorder.
2021-12-21 | Case Report: A Case of Cotton-Wool Spots After Intravitreal Injection of Conbercept in an Infant With Incontinentia Pigmenti
Introduction: Incontinentia pigmenti (IP) is a rare X-linked neuroectodermal dysplasia affecting multiple organs. One of its most significant ophthalmic manifestations is retinal neovascularization due to retinal ischemia, which has been traditionally treated with laser photocoagulation or cryotherapy. The application of anti-vascular endothelial growth factor (VEGF) has been reported for the treatment of retinopathy of IP with beneficial results. However, clinicians should be aware of the possible ocular and systemic side effects of the intravitreal injection of anti-VEGF agents. Case Report: A 4-month-old female infant with IP was treated with intravitreal injection of conbercept in both eyes. However, cotton-wool spots were noticed in the left eye 1 week after the injection. Laser photocoagulation was performed as an adjunct treatment. The cotton-wool spots were absorbed 1 month after the first intravitreal injection and have eventually disappeared. Discussion: The cotton-wool spots, after intravitreal injection of conbercept for the treatment of IP, indicated severe retinal ischemia resulting from the neutralization of excessive VEGF, which was shown on fundus photograph and fluorescent angiography. Anti-VEGF agents could cause retinal arteriolar vasoconstriction and artery occlusion on rare occasions. The administration of anti-VEGF agents in pediatric cases with severe neovascularization and retinal ischemia should be carefully considered.
2020-10-22 | Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report.
Incontinentia Pigmenti is a rare disease affecting multiple organs. Fifty of patients show affection of the eye with retinopathy and possible amaurosis being the worst outcome. Treatment has commonly been panretinal laser coagulation but intravitreal application of bevacizumab as VEGF-inhibitor has shown to effectively suppress retinal neovascularization. A six-week-old female infant with Incontinentia Pigmenti developed a foudroyant necrotizing enterocolitis shortly after intravitreal injection of bevazicumab due to a retinopathy with impending tractional detachment of the left eye. Since the onset of abdominal symptoms occurred immediately after the intravitreal application, a link between the two events seemed likely. Sequential analyses of the VEGF serum concentrations showed a massive suppression of endogenous VEGF with only a very slow recovery over weeks. Such a severe systemic adverse event has not been reported after intravitreal treatment with bevacizumab in an infant. This case report shows a relevant systemic uptake of bevacizumab after intravitreal application as suppressed VEGF levels show. There seems to be a connection between suppressed VEGF levels and the onset of necrotizing enterocolitis. Therefore, treatment with bevacizumab should be carefully considered and further research is needed to assess this drug's safety profile.
2019-04-18 | [Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor].
Objective: To investigate the treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor. Methods: Retrospective study of 5 patients(8 eyes) diagnosed retinopathy of incontinentia pigmenti from 2005 to 2017, including 0 males and 5 females (8 eyes involved) with an average age of 2.4 months(range, 1-5 months). Medical history and family history were recorded in detail for all children. We did the examination of anterior segment of the eyeball, vitreous body,fundus and intraocular pressure for the 5 patients(8eyes).What's more,wo also took pictures for fundus with the machine of Retcam. Fundus fluorescence angiography (FFA) was performed in 2 patients(4 eyes). Different surgical methods were selected according to the specific conditions of the eye and postoperative were observed. Results: At the time of initial diagnosis, preretinal hemorrhage did not affect the macular region in 3 cases (5 eyes), pre retinal hemorrhage affected the macular region in 1 case(1 eye), the retinal neovascularization in 3 cases(5 eyes), the retinal detachment in 2 cases(2 eyes), and nonvascular zone of peripheral retinal in 5cases(8 eyes). Treatment and drug selection: 3 cases(5 eyes) were treated with injection anti-VEGF drug into vitreous body cavity, 1 case(1 eye) was treated with injection anti-VEGF drug into vitreous body cavity plus laser photocoagulation, 1 case(1 eye) was treated with anti-VEGF drugs plus vitrectomy. 1 case(1 eye) was treated with anti-VEGF drugs plus retinal cryotherapy and sclera bucking. In patients of injection anti-VEGF drug into vitreous body cavity, 2 cases(3 eyes) were given a single dose and 1 case (2 eyes) was given a repeated dose. Drug selection: 4 cases(6 eyes) ranibizumab injection (injection dose 0.025 ml), 1 case (2 eyes)conbercept injection (injection dose 0.025 ml). To follow-up date, etina was flat in 4 patients (7 eyes), epiretinal membrane in 2 patients(2 eyes), retinal detachment in 1 patient(1 eye). Conclusions: The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. (Chin J Ophthalmol, 2019, 55:294-301). 目的: 探讨色素失禁症相关性视网膜病变的临床表现及抗血管内皮生长因子治疗效果。 方法: 回顾性系列病例研究。收集2005至2017年确诊的5例色素失禁症相关性视网膜病变患儿的临床资料。患儿均为女性,就诊年龄1~5个月,平均2.4个月。详细记录患儿病史及家族史,5例(10只眼)均行眼前节检查、玻璃体检查、眼底检查和眼压检查,并用Retcam系统行眼底照相,其中2例(4只眼)曾行荧光素眼底血管造影检查。根据患儿眼底具体情况选择单纯玻璃体腔注药术、玻璃体腔注药术联合激光光凝治疗或玻璃体腔注药术联合玻璃体切除术等,观察术后效果。 结果: 初诊时视网膜前出血未累及黄斑区3例(5只眼),黄斑区视网膜前出血1例(1只眼),视网膜新生血管3例(5只眼),视网膜脱离2例(2只眼),周边无血管区5例(8只眼)。视网膜前出血未累及黄斑区5只眼中有3只眼累及视网膜4个象限,2只眼累及颞上、颞上2个象限。治疗方案及药物选择:3例(5只眼)单纯玻璃体腔注射抗VEGF药物治疗,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加激光光凝,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加玻璃体切除术,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加视网膜冷冻术及外加压术。在单纯玻璃体腔注射抗VEGF药物治疗患者中有2例(3只眼)单次给药,1例(2只眼)多次重复给药。注射药品选择4例(6只眼)雷珠单克隆抗体(注射剂量0.025 ml),1例(2只眼)康柏西普(注射剂量0.025 ml)。至随访日,4例(7只眼)患儿视网膜在位,2例(2只眼)可见视网膜前增生膜,1例(1只眼)视网膜脱离。 结论: 初步证实了抗血管内皮生长因子药物在色素失禁症相关性视网膜病变治疗中的有效性。但最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。(中华眼科杂志,2019,55:294-301).
small molecules
2026-04-01 | AN AYURVEDIC APPROACH IN THE MANAGEMENT OF HYPOMELANOSIS OF ITO: A CASE REPROT
Background: Hypomelanosis of Ito (HOI) is a neurocutaneous disorder characterized by bizarre, bilateral and irregularly shaped leukoderma affecting the trunk and extremities, often associated with neurological and musculoskeletal abnormalities. It is also called incontinentia pigmenti achromians and is the third most common neurocutaneous disorder after Neurofibromatosis and Tuberous sclerosis. Considering the symptomatology, this condition can be correlated as Sahaja Sarvangavatam (diseases due to vata affecting the whole body) with Vyanavrutha Vatha (subtype of vata) and skin involvement is predominantly visible. Objective: The article highlights the scope of an integrated approach in treating neurocutaneous disorders, combining Ayurvedic intervention along with physiotherapy. Methodology: This is a case study of a 4-year-old child presenting with hypomelanotic areas on extensor part of right arm by birth, seizure disorder, mild hearing loss, inability to sit without support and mild spasticity of bilateral lower limbs. He visited the outpatient department of our tertiary Ayurvedic Health Centre and took outpatient management for about two weeks with the administration of Ashwagandharishtam, Rajanyadi churnam, Kalyanavaleha churnam, Priyalamajjadi modakam and Mahanarayana tailam. IP management was also taken along with dietary recommendations for about one month and twelve days with the line of management of Vatavyadhi (diseases caused by Vata) Chikitsa (treatment) along with Samana oushadhas (palliative medicines). The outcome was assessed using Ages and Stages Questionnaire before and after the treatment. Result: Head holding was improved from Grade 4 to Grade 5 with reduction in the spasticity of bilateral lower limbs. Crawling was attained with reduction in drooling and colour of the hypopigmented patches got mildly regressed along with initiation of new sounds and words with no further episodes of seizures. The Ages and Stages Questionnaire improved from 195 to 245, providing valuable insights into management strategies. Conclusion: An integrated approach involving Ayurveda and physiotherapy provides a sustainable solution in improving the quality of life of the child.
2026-04-01 | Clearance of Verrucous Stage of Incontinentia Pigmenti with Condy’s Solution
A 10-month-old female child born out of a consanguineous marriage presented with thick, dirty, warty hyperpigmented lesions with episodes of serosanguineous discharge on the left lower limb since 2 months of age. Her left side abdomen and arm also had mild lesions in a blaschkoid pattern. A diagnosis of verrucous stage Incontinentia Pigmenti was made with the help of histopathology evaluation. Initially, she was given oral and topical antibiotics for management, but the lesions did not heal completely. Then, the parents were advised to prepare Condy’s solution and use it for soaking the lesions for 5–10 min on oozing lesions. After performing this therapy for 2 months, a drastic response was seen in the lesions as the discharge had stopped and crusting had reduced by 60% [Figures 1 and 2]. Gradually, the frequency of application was reduced to twice a week and then completely halted after 1 month.Figure 1: Visual comparison of Pre (a) and Post (b) therapy images of lateral aspect of child’s left lower limb showing the decrease in hyperpigmented, warty, oozing lesions after Condy’s soaksFigure 2: Visual comparison of Pre (a) and Post (b) therapy images of dorsal aspect of left foot with clear improvementCondy’s solution used for medicinal purposes is made by dissolving 400 mg of potassium permanganate in 4 L of water to attain 1:10,000 dilution.[1] However, in clinical practice, patients are explained to dilute the solution to reach a color similar to the pink color of one’s nail bed. It has astringent properties that help in drying up the weeping lesions along with rendering antibacterial and anti-inflammatory properties. Using Condy’s soaks for Incontinentia pigmenti in this case makes it worthwhile exploring further in clinical practice. Declaration of consent The authors certify that they have obtained all appropriate consent forms, duly signed by the parent(s)/guardian(s) of the patient. In the form, the parent(s)/guardian(s) has/have given his/her/their consent for the images and other clinical information of their child to be reported in the journal. The parents understand that the names and initials of their child/children will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
2025-02-28 | Single-Cell RNA Sequencing in Incontinentia Pigmenti With Neonatal Encephalopathy Reveals Broad Immune Activation Moderated by Steroids.
DNA variations in the NF-kappa-B essential modulator (NEMO) gene are linked to incontinentia pigmenti (IP) and also immunodeficiency and autoinflammatory conditions. Some patients with IP present with neonatal vasculitis-like brain changes, although pathogenesis is unclear. We investigated cell-specific gene expression in a neonate with IP, who had encephalopathy, seizures, and vasculitis-like brain changes, and responded to steroid treatment. Single-cell RNA (ribonucleic acid) sequencing (scRNAseq), using the HIVE single-cell system, was performed on a neonate with IP, before and after steroid treatment, compared with a sex-matched healthy control toddler. A total of 20,411 cells were sequenced and clustered into 10 cell types. In IP compared with control, upregulated significant gene set enrichment analysis gene ontology pathways (FDR <0.05) included defense response, complement activation, humoral immune response, and phagocytosis across all cell types. After steroid treatment, these pathways were predominantly downregulated in monocytes and neutrophils. The upregulated genes in IP that became downregulated after steroid treatment were interferon-related genes, oligoadenylate synthases, and immunoglobulin genes. IP-associated loss of NEMO function is associated with a proinflammatory phenotype, that is moderated by steroids. scRNAseq provides a rationale for immune modulation in an n = 1 setting and valuable insights into the pathogenesis and therapeutics of this rare disease.
2025-01-30 | Case Report: Diagnosis and treatment of incontinentia pigmenti with central nervous system anomalies in one patient.
This article reports a detailed case of a patient with incontinentia pigmenti who exhibited epileptic status and dermatologic symptoms. A 5-month-old female patient was brought to our hospital due to status epilepticus, with erythematous vesicular skin lesions on her trunk and extremities. Routine magnetic resonance imaging revealed infarction, ischemia, and encephalomalacia. Skin biopsy pathology indicated pigmentation disorder. Molecular genetic testing was conducted to identify IKBKG mutations, and the case was finally diagnosed with incontinentia pigmenti complicated by central nervous system anomalies. She was treated with oral levetiracetam (10 mg/kg/day, administered every 12 h) to control her recurrent seizures, and prednisone (1 mg/kg/day, once a day) for anti-inflammatory effects. After nine months, her skin lesions have resolved, with only a few newly developed erythematous papules and areas of hyperpigmentation being evident. There were no recurrent epilepsy symptoms, developmental impairments, or other associated symptoms.
2024-10-24 | Incontinentia pigmenti: a rare cause of skin rash in newborn
Incontinentia pigmenti (IP) is a genodermatosis caused by mutations in the NEMO gene (Xq28) and is lethal in males. It is an X-linked dominant disorder with multi-systemic involvement. It involves the central nervous system and ectodermal tissues like skin, teeth, hair, nails, eyes, and the commonest manifestations are cutaneous manifestations. Here we present a case of a female newborn with vesico bullous eruption presented at birth. A full-term newborn female patient born by LSCS presented at birth with multiple vesico bullous skin lesions over bilateral upper and lower limbs in a pattern consistent with Blaschko's lines. Maternal HIV, HBsAg, VDRL, and TORCH screening were negative. Systemic examinations were normal. Supportive care and IV antibiotics with IV acyclovir were started but without any response. The sepsis screen, blood, and urine culture were negative. ANA was negative. Wound swab culture and skin culture were negative. Skin biopsy results showed eosinophilic infiltration of the dermis and spongiosis. Genetic testing could not be done. Topical steroids were prescribed. The diagnosis of Incontinentia pigmenti was established based on the patient's skin lesions and biopsy results. The baby improved and was discharged on the 14th day of life on topical steroids and is currently under follow-up. Other dermatologic conditions, like mastocytosis and hereditary epidermolysis bullosa, should be considered in the differential diagnosis of Incontinentia pigmenti. The diagnosis of Incontinentia pigmenti should be confirmed by histopathological examination of biopsy specimens along with genetic testing. It is a systemic disorder, so clinical management should include a multidisciplinary approach.
gene therapies
2026-06-22 | Simultaneous trophectoderm biopsies enable preimplantation genetic testing for monogenic disorders in de novo case of incontinentia pigmenti: case report.
To describe the use of two simultaneous trophectoderm biopsies as a method to establish linkage analysis for preimplantation genetic testing for monogenic disorders (PGT-M) test development in a case of de novo incontinentia pigmenti (IP). Case report. A 29-year-old nulligravid woman with de novo IP, confirmed to have the common, large deletion of exons 4-10 in the IKBKG gene. Negative maternal testing confirmed the mutation was de novo in our patient. Two simultaneous trophectoderm biopsies from a minimum of four embryos were obtained to enable two independent deoxyribonucleic acid preparations. This approach was utilized to complete linkage analysis, facilitating successful test development for PGT-M. PGT-M test development and subsequent intracytoplasmic sperm injection/PGT-M cycle targeting the IKBKG deletion. PGT-M test development was successful. The patient underwent two antagonist stimulation protocols with intracytoplasmic sperm injection and PGT-M, yielding 10 euploid embryos that tested negative for the IKBKG deletion and were deemed suitable for transfer. PGT-M for de novo IP is particularly challenging given the presence of the IKBKGP1 pseudogene, its terminal location, and the fact that indirect linkage analysis is necessary for large gene deletions. Without genetic information from parents and offspring, PGT-M test development is frequently unsuccessful. This case demonstrates that simultaneous trophectoderm biopsies can enable PGT-M in otherwise ineligible cases, offering a viable path forward for patients affected by de novo IP.
2026-05-30 | Incontinentia pigmenti: exploring the oral manifestations.
Incontinentia pigmenti (IP) is a rare genetic condition which is X-linked and predominantly affects the structures arising from neuroectodermal origin such as the skin, teeth, eyes, hair, nails and central nervous system. The dermatological manifestations are seen as the first developing signs. The dental manifestations are also commonly seen. Here we discuss a case of a girl in her early adolescence who was diagnosed with a case of IP. The dental features present in this case were typical, including missing permanent teeth, retained deciduous teeth, microdontia and delayed eruption.
2026-05-06 | Asymptomatic Sight-Threatening Retinopathy in Multisystem Incontinentia Pigmenti
A 9-year-old girl had a history of fulminant systemic autoinflammation from birth, manifesting as acute respiratory failure, hand tremors, and generalized cutaneous erythema.Brain magnetic resonance imaging revealed cerebral injury, and laboratory tests showed markedly elevated inflammatory markers, including C-reactive protein and erythrocyte sedimentation rate.At 20 months of age, she was hospitalized for life-threatening Aspergillus pneumonia complicated by liver dysfunction.During this period, a diagnosis of incontinentia pigmenti (IP) was established.
2026-01-27 | A Fulminant Case of Incontinentia Pigmenti Presenting With Early Neuro-Ophthalmologic Manifestations.
Incontinentia pigmenti (IP) is a rare, X-linked dominant, multisystemic genetic disorder. We report the case of a female neonate presenting with vesiculobullous and erythematous cutaneous lesions involving the hands and feet. Concurrently, she exhibited repetitive flexion movements of all four limbs, which rapidly progressed to status epilepticus. The clinical course was rapidly unfavorable, marked by diffuse retinal ischemia and cerebral palsy. This patient's clinical history illustrates the potential severity of the neurological and ophthalmologic manifestations of IP. It underscores the need to consider IP in the differential diagnosis of cutaneous lesions associated with neurological symptoms in female infants. Early recognition is essential to ensure close monitoring and initiate appropriate multidisciplinary management.
2025-12-19 | O05 Incontinentia pigmenti: clinical heterogeneity and the role of early dermatological recognition.
Incontinentia pigmenti (IP) is a rare X-linked dominant genetic condition affecting the skin, teeth, eyes and central nervous system. It is most frequently caused by a common deletion of exons 4-10 in the IKBKG gene. Skin manifestations classically evolve through four stages: blistering, verrucous, hyperpigmentation and hypopigmentation. We conducted a retrospective review of patients attending our tertiary centre since 2000. The study aim was to classify the cutaneous phases of IP and other system involvement in our cohort. 44 patients were included, identified through our electronic health record system. Patient data were anonymised and analysed in SPSS. 93% were female. Mean age of presentation was 20 months, with 68% <6 months. 67% had cutaneous manifestations at birth. Not all patients followed the four classical stages of IP: 91% experienced blistering, 61% verrucous stage, 84% hyperpigmentation and 22.7% hypopigmentation. 18% had hair and 16% nail abnormalities. Mean follow-up duration was 5 years. To confirm IP diagnosis, 23% had a skin biopsy and 96% had genetic testing. 75% had the common IKBKG deletion. Of 3 male patients, all had normal karyotypes and 2 had common deletion of IKBKG, suggestive of mosaic IP. Most patients had extra-cutaneous involvement. 60% had ocular manifestations, with 48% requiring laser treatment. 27% had neurological involvement and 71% dental abnormalities. IP typically presents with cutaneous manifestations, giving dermatologists a crucial role in diagnosis. Our review highlights that patients may not exhibit the textbook presentation of IP. Early recognition has important implications for sight preservation and monitoring of neurodevelopment.
proteins
2026-06-28 | Coexistence of Incontinentia Pigmenti and Pituitary Aplasia in a Female Child
Incontinentia pigmenti (IP) is a rare X-linked dominant neurocutaneous ectodermal disorder. It is caused by IKBKG gene mutations, leading to nuclear factor-kappa B (NF-kB) signaling pathway dysfunction. Skin involvement occurs in almost all patients. IP may also involve teeth, eyes, hair, central nervous system, bone structures, skeletal musculature and immune system. However, endocrine involvement, and specifically the coexistence of IP with complete pituitary aplasia, has not been previously documented in a patient with genetically confirmed IP. We describe a four-year-old female with genetically confirmed IP referred to Paediatric Endocrinology clinic due to short stature and poor growth velocity. Investigation revealed pituitary aplasia with ectopic neurohypophysis. The patient initiated hormone replacement therapy with recombinant human growth hormone and hydrocortisone, followed separately by desmopressin, with significant clinical improvement and no exacerbation of cutaneous manifestations. To our knowledge, this is the first documented case of complete pituitary aplasia in a patient with genetically confirmed IP, with a three-year clinical follow-up.
2024-10-01 | Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.
Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO variants, from 99 kindreds in 10 countries. Forty-seven of these patients (36%) have auto-Abs neutralizing IFN-α and/or IFN-ω, a proportion 23 times higher than that for age-matched female controls. This proportion remains stable from the age of 6 years onward. On imaging, female patients with IP have a small, abnormally structured thymus. Auto-Abs against type I IFNs confer a predisposition to life-threatening viral diseases. By contrast, patients with IP lacking auto-Abs against type I IFNs are at no particular risk of viral disease. These results suggest that IP accelerates thymic involution, thereby underlying the production of auto-Abs neutralizing type I IFNs in at least a third of female patients with IP, predisposing them to life-threatening viral diseases.
2010-06-07 | Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology
NF-kappaB Essential MOdulator (NEMO) has been shown to play a critical role in NF-kappaB activation, as the regulatory subunit of IkappaB kinase. Upon cell stimulation, NEMO can be modified through phosphorylation, sumoylation or ubiquitination. In the latter case, not much is known regarding the exact function of this posttranslational modification. One of the E3 ligase responsible for K63-linked NEMO polyubiquitination is TRAF6, which participates in several signaling pathways controlling immunity, osteoclastogenesis, skin development and brain functions. We previously observed a potentially important interaction between NEMO and TRAF6. In this study, we defined in more detail the domains required for this interaction, uncovering a new binding site for TRAF6 located at the amino-terminus of NEMO and recognized by the coiled-coil domain of TRAF6. This site appears to work in concert with the previously identified NEMO ubiquitin-binding domain which binds polyubiquitinated chains, suggesting a dual mode of TRAF6 recognition. We also showed that E57K mutation of NEMO found in a mild form of the genetic disease incontinentia pigmenti, resulted in impaired TRAF6 binding and IL-1beta signaling. In contrast, activation of NF-kappaB by TNF-alpha was not affected. These data demonstrate that NEMO/TRAF6 interaction has physiological relevance and might represent a new target for therapeutic purposes.
2006-11-29 | Deletion of the N-terminus of IKKγ induces apoptosis in keratinocytes and impairs the AKT/PTEN signaling pathway
The regulatory subunit IKKγ/NEMO is crucial for skin development and function and although devoid of kinase activity, loss of IKKγ function completely abolishes the activation of NF-κB by all pro-inflammatory cytokines. To inhibit the IκB kinase (IKK) complex in keratinocytes, we have used a dominant negative approach by generating stable transfectants of an N-terminal deletion of IKKγ (IKKγ-DN97) that uncouples formation of the IKK complex. Expression of this mutant in PB keratinocytes (PB-IKKγ-DN97) delayed growth kinetics, caused morphological changes and dramatically augmented apoptosis even in the absence of pro-apoptotic stimuli, as determined by cell morphology, TUNEL and caspase-3 cleavage. Moreover, in PB-IKKγ-DN97 cells, TNF-α and IL-1 treatment failed to induce degradation of IκBα, phosphorylation of p65 on Ser 536 and nuclear translocation which, consequently, reduced κB-binding activity. In PB-IKKγ-DN97 cells, accumulation of IκBα correlated with a downregulation of AKT activity and an increase of PTEN protein levels whereas pro-apoptotic p53 target genes Bax and Puma were upregulated. These effects were most likely mediated through IKK since coexpression of the wild-type form of IKKγ in keratinocytes partially reversed apoptosis and reduced PTEN expression. Thus, our data suggest a negative cross-talk mechanism involving PTEN and NF-κB, critical for the anti-apoptotic role of NF-κB in keratinocytes.
other
2025-07-08 | [Application of long-read sequencing based haplotype construction in preimplantation genetic testing for a patient with Incontinentia pigmenti].
To provide preimplantation genetic testing (PGT) for a patient with Incontinentia pigmenti (IP) due to IKBKG gene variant but without family samples through construction of single nucleotide polymorphism (SNP)-based haplotype by Long-read sequencing (LRS) technology. A female IP patient with a heterozygous IKBKG c.1167dup variant but without family genetic data who sought genetic counseling at Women and Children' Hospital of Ningbo University in November 2021 was selected as the study subject. The IKBKG gene has a highly homologous pseudogene IKBKGP1. Genomic DNA was extracted from peripheral blood samples from the couple, and LRS was used to obtain informative SNP loci flanking the variant locus, enabling the construction of SNP haplotype with a long segment spanning from the non-homologous region of IKBKG to the variant site. Trophoblast cells were biopsied from blastocysts fertilized through intracytoplasmic sperm injection, and next-generation sequencing (NGS) was used to determine the SNP information of the embryos. Linkage analysis with the parental SNP haplotypes was conducted to detect the carrier status of the embryos and exclude chromosomal aneuploidies. Sanger sequencing was carried out to validate the result. A euploid embryo without the pathogenic variant was selected for transfer. Prenatal diagnosis was carried out by amniocentesis at mid-trimester to verify the result of PGT tests, and follow-up was conducted after the baby was born. This study has been approved by the Ethics Committee of Women and Children's Hospital of Ningbo University (Ethics No. EC2023-094). A total of seven blastocysts were tested, and PGT results indicated that two embryos were euploid and did not carry the pathogenic variant. One euploid embryo was transferred, which resulted in a singleton pregnancy. Amniocentesis at 24 weeks of gestation confirmed that the status of fetal IKBKG gene, and its chromosomal status was consistent with the PGT results. A healthy male infant was born at 38+6 weeks of gestation. For IP patients with de novo mutation or without family genetic samples, PGT with LRS can directly construct the SNP-based haplotype while avoiding interference from pseudogenes, providing an effective strategy for PGT.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.